secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2024-09-19T23:59:59+00:00
Accession:  0001683168-24-006522
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon receives ethics approval for Hemopurifier cancer trial in India; enrollment targeted Q4 2024
--------------------------------------------------------------------------------

- Medanta Institutional Ethics Committee approved safety, feasibility, dose-finding trial of Hemopurifier in solid tumors not responding to anti-PD-1 antibodies.
- Trial at Medanta Medicity Hospital, Gurugram, India; Dr. Ashok K. Vaid and Dr. Puneet Sodhi as investigators.
- Patient recruitment expected Q4 2024; primary endpoint is safety, with exploratory EV reduction analyses.
- This adds to prior Australian ethics approvals and DCGI No Objection Certificate for the oncology trial.
- Hemopurifier designed to remove tumor-derived extracellular vesicles that may drive resistance to PD-1 inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316824006522/0001683168-24-006522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316824006522/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-006522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer